| Literature DB >> 28549934 |
Úrsula Catalán1, Laura Barrubés1, Rosa Maria Valls1, Rosa Solà2, Laura Rubió3.
Abstract
Dietary phenolic compounds (PCs) have been receiving interest for their presumed roles in disease prevention. However, there is a lack of studies on the underlying molecular mechanisms. In this regard, in vitrometabolomic approaches are suitable for the investigation of the molecular changes in response to PC exposure. Up to date, the biological effects of PCs have only been examined for PCs from rosemary (Rosmarinus officinalis), olive oil, and resveratrol using cell-based metabolomic approach, although transcriptomic and/or proteomic studies have also been conducted in the same in vitro cell experiment in some cases. Our integral analysis of the reviewed studies suggest that PCs may be involved not only in basic cellular processes or macro- and micro-nutrient metabolism, but also in specific metabolic pathways that have been thoroughly investigated. These modulated pathways could have a clinical impact on neurodegenerative diseases, type 2 diabetes, cancer, and cardiovascular diseases. In conclusion, the in vitro metabolomic approaches provide additional information of the molecular mechanisms involved in disease risk reduction of dietary PCs. In order to elucidate the mechanisms of action of PCs, more metabolomic cell-based studies are needed and testing the physiological conjugated forms of PCs in these cell systems could be of special interest.Entities:
Keywords: Cell-based; Disease prevention; Mechanism of action; Metabolomics; Phenolic compounds
Mesh:
Substances:
Year: 2017 PMID: 28549934 PMCID: PMC5582796 DOI: 10.1016/j.gpb.2016.12.007
Source DB: PubMed Journal: Genomics Proteomics Bioinformatics ISSN: 1672-0229 Impact factor: 7.691
Figure 1Flowchart of the search strategy
Bibliographic review was carried out in PubMed and Scopus scientific databases until January 2016. The following terms were used for the search: ‘polyphenols’, ‘phenolic compounds’, ‘cells’, ‘mechanism of action’ and ‘metabolomics’. Reviews and studies evaluating metabolomics on plants, mice, rats or human samples were excluded and only cell-based studies were retained.
| Human colon cancer cells: HT29 | Rosemary phenolic extract (carnosic acid: 256.0 µg/mg); 9.9 µg/ml | Transcriptomics | Microarray; RT-qPCR | — | 281 DEGs out of 341 identified genes | Methylglyoxal degradation; dopamine, tryptophan, melatonin, noradrenaline, and serotonin degradation; ethanol degradation; bile acid and retinoate biosynthesis; LPS/IL-1-mediated inhibition of RXR function; transport of molecules; metabolism of terpenoid; metabolism of ROS; polyamine metabolism | |
| Metabolomics (nontargeted) | CE-MS and HILIC/UPLC-MS | HMD, METLIN, and KEGG | 21 DEMs | Glutathione metabolism; polyamine metabolism | |||
| Rosemary phenolic extract (carnosol: 226.4 µg/mg; carnosic acid: 151.5 µg/mg); 10 µM (total rosemary phenols) | Transcriptomics | Microarray; RT-qPCR | — | 1308 DEGs | Cellular development; cell death; cellular growth and proliferation; cell cycle; glutamate and glutathione metabolism | ||
| Proteomics | MALDI-TOF/TOF-MS | — | 17 DEPs | Cell proliferation; cell adhesion; cell migration | |||
| Rosemary phenolic extract (carnosol: 226.4 µg/mg; carnosic acid: 151.5 µg/mg); 10 µM (total rosemary phenols) | Metabolomics (nontargeted) | CE-MS, RP/UPLC-MS, and HILIC/UPLC-MS | HMD, METLIN, KEGG compound, and PubChem | 65 DEMs | Glutathione metabolism; urea cycle and metabolism of amino groups; polyamines homeostasis; cell proliferation and viability | ||
| Rosemary phenolic extract; 10 µM | Metabolomics (nontargeted) | CE-ESI-TOF MS | HMD, METLIN, KEGG compound, and PubChem | 44 metabolites identified | Glycan biosynthesis and metabolism; organismal systems; excretory system; neuroactive ligand-receptor interaction; amino, carbohydrate, lipid, nucleotide, energy, cofactor, and vitamin metabolism; environmental and genetic information processing | ||
| Human colon cancer cells: SW480 and HT29 | Extra virgin olive oil extract (decarboxymethyl oleuropein aglycon: 238.4 mg/kg); 0.01%–0.1% | Metabolomics (nontargeted) | nanoLC-ESI-TOF-MS | — | 20 metabolites were identified in cells and culture medium | Uptake and metabolism of polyphenols; cell-cycle metabolism | |
| Human hepatocellular liver carcinoma cells: HepG2 | Resveratrol; 40 µM | Metabolomics (nontargeted) | 1H NMR spectroscopy | — | 9 DEMs out of 34 identified metabolites | Energy metabolism: Krebs cycle | |
| Human erythroleukemia cells: K562 and K562/R | Rosemary phenolic extract (carnosol: 226.4 µg/mg; carnosic acid: 151.5 µg/mg); 5, 10 µM | Transcriptomics | Microarray; RT-qPCR | — | 289 DEGs in K562; | Cellular movement; cell-to-cell signaling and interaction; free radical scavenging; cell death; NRF2-mediated oxidative stress response; LPS/IL-1-mediated inhibition of RXR function; aryl hydrocarbon receptor signaling; protein synthesis; antigen presentation; cellular function and maintenance | |
| Metabolomics (nontargeted) | CE-MS and UPLC-MS | — | 121 DEMs in K562; | Aminoacyl-tRNA biosynthesis; glutathione metabolism; arginine and proline metabolism; nitrogen metabolism; glutamate metabolism; urea cycle and metabolism of amino groups | |||
Note: LPS, lipopolysaccharide; IL-1, interleukin-1; RXR, retinoid X receptor; CE-MS, capillary electrophoresis–mass spectrometry; HILIC/UPLC-MS, hydrophilic-interaction ultra-performance liquid chromatography coupled to mass spectrometry; HMD, human metabolome database; ROS, reactive oxygen species; MALDI-TOF/TOF-MS, matrix-assisted laser desorption/ionization-time of flight mass spectrometry; RP, reverse phase; ESI, electrospray ionization; NMR, nuclear magnetic resonance; NRF2, nuclear factor-like. DEG, differentially-expressed gene; DEP, differentially-expressed protein; DEM, differentially-expressed metabolite.
Figure 2Chemical structure and main food sources of the phenolic compounds included in this update
Figure 3Metabolic pathways modified by the phenolic compounds reviewed in this update
All the metabolic pathways shown in the figure are modified by rosemary phenolic extract. The increase and decrease in the biological functions are indicated with arrows ↑ and ↓, respectively. Biological functions without arrows indicate that the increase or decrease of these functions is not specified in the original articles.
Metabolic pathways modified by PCs reviewed and their association with common diseases
| Neurotransmitter degradation | ||||||||||
| Ethanol degradation | ||||||||||
| Melatonin | ||||||||||
| Methylglyoxal degradation | ||||||||||
| Polyamine metabolism | ||||||||||
| Terpenoid metabolism | ||||||||||
| Tryptophan degradation | ||||||||||
| Glutathione metabolism | ||||||||||
| Aminoacyl-tRNA biosynthesis | ||||||||||
| Aryl hydrocarbon receptor signaling | ||||||||||
| Bile acid biosynthesis | ||||||||||
Note: Neuro-degenerative disorders include Alzheimer’s disease, Parkinson’s disease, and Huntington's disease. Cardio-vascular diseases include inflammatory response, oxidation response, and atherosclerosis. PC, phenolic compound; T2DM, type 2 diabetes mellitus; CVD, cardiovascular disease; AID, autoimmune disease.